Written and medically reviewed byDr. Cem Özlük MD.Urologist

Last updated: 16 September 2026
Reading time: 13 min

Penile filler is minimally invasive, but minimally invasive does not mean risk-free.

AI tools

Summarize This Guide with AI

The page title, key topics and source link are passed to your selected tool in a prepared prompt.

ChatGPT Grok Perplexity Claude

On this page

Penile filler is minimally invasive, but minimally invasive does not mean risk-free.

A 2026 systematic review and meta-analysis evaluated 23 primary studies involving 2,620 participants. Across all included penile-augmentation approaches, the pooled complication rate was 14.9%. Hyaluronic acid (HA) appeared numerically lowest at 9.0%, but all comparisons between materials were indirect and no head-to-head randomised trials existed. These pooled percentages must not be presented as an individual patient’s personal risk.

Current evidence therefore supports a more careful statement: HA may have a more favourable observed complication profile than some permanent materials, but safety depends on much more than the name of the filler.

Patient selection, penile anatomy, material identity and traceability, volume planning, clinical conditions, follow-up and complication preparedness all matter.

“Which filler do you use?” is useful, but it is not enough.

A better safety framework asks:

Who is assessing me? What exactly is being injected? Why was this plan chosen? How will follow-up work? What happens if something goes wrong?

What happened in the 2026 Thailand penile filler case?

In September 2026, international reporting focused on the death of 43-year-old Igho “Tiny” Ubiribo after a penile girth-enhancement injection procedure in Bangkok.

Reporting on the UK inquest stated that approximately 40 mL of hyaluronic acid and lidocaine had been used. Ubiribo later developed chest pain, collapsed and was taken to hospital, where pulmonary embolism was diagnosed. Reports of the UK post-mortem stated that material in the lungs matched the HA used in the injections, and the assistant coroner reportedly concluded that the cosmetic procedure caused the fatal pulmonary embolism. Thai authorities subsequently examined the facility and the circumstances of treatment.

What does this case tell us?

It reinforces a simple but important point:

An injectable cosmetic procedure should not be treated as medically trivial simply because it does not involve major surgery.

Penile filler still involves an invasive intervention, a material placed into genital tissue and the possibility of local or systemic complications.

What does this case not tell us?

One fatal case cannot define the general risk of death or serious complications from penile HA filler.

A case can show that a severe event can occur. It cannot establish how often it occurs.

The reported 40 mL is also a fact from this individual case, not a universal threshold that separates “safe” from “dangerous” treatment.

The correct interpretation is neither “penile filler is harmless” nor “one death proves penile filler is generally lethal”.

What does the scientific evidence say?

Evidence for cosmetic penile augmentation remains less mature than evidence for many established medical treatments.

The 2026 meta-analysis included 9 randomised trials and 14 observational studies from eight countries. The pooled complication rate was 14.9% (95% CI 11.5–18.6). HA appeared numerically lowest at 9.0% (95% CI 5.1–13.9), with moderate GRADE certainty, but the authors stressed that cross-material comparisons were indirect.

That means:

HA may be among the more favourable minimally invasive options currently studied.
The evidence does not prove that all HA products are equivalent.
9% is not an individual patient’s personal risk.
The evidence does not prove that HA is universally the safest option.
Better direct and long-term studies are still needed.

EAU guidance recommends extensive counselling about risks and benefits of penile girth-enhancement techniques and notes the limited evidence in this field.

ICSM recommendations similarly emphasise comprehensive assessment, realistic expectations, clinician expertise, available resources and explicit discussion of complications.

The more useful question is therefore not only:

“Is penile filler safe?”

but:

“How should risk be assessed and reduced for this particular patient, with this particular material and treatment plan?”

Seven areas of penile filler safety

1. Patient selection

Safety starts before a procedure is booked.

Assessment may include active infection or inflammation, skin and soft-tissue findings, previous penile filler or other injected substances, prior genital surgery, conditions affecting bleeding or healing, medication use and the person’s expectations.

Not every request for more girth should automatically lead to treatment.

EAU guidance also supports considering body-dysmorphic or penile-dysmorphic concerns when clinically relevant.

Sometimes the first safety decision is not to perform a procedure.

2. Anatomical assessment

Penile filler should not be treated as if it were simply a facial filler performed in a different location.

The penis has distinctive vascular, neural and soft-tissue anatomy. Circumcision status, scarring, previous surgery, previous filler, asymmetry and curvature can all affect planning.

A photograph or the question “How many mL do you want?” is therefore not equivalent to a clinical assessment.

3. Material identity and traceability

A patient should know what is being injected.

Reasonable questions include:

What is the exact product?
Who manufactures it?
Is it actually HA?
Is the batch/lot recorded?
Is the product identity documented in the medical record?
Is previous filler or another unknown material already present?

The point is not to market one brand as “best”.

The more objective concept is traceability.

If another clinician later needs to assess a complication, uncertainty about the injected material can make that assessment harder.

“High-quality filler” is therefore less useful than:

known product → identifiable manufacturer → documented batch → appropriate storage → clinically justified choice.

4. Volume is only one part of the plan

“How many mL do I need?” is one of the most common questions.

There is no universal evidence-based number suitable for everyone.

Baseline circumference, shaft length, tissue characteristics, previous filler, asymmetry and the intended proportional change all matter.

Therefore:

more filler ≠ automatically better

more filler ≠ automatically longer-lasting

a study volume ≠ a personal prescription

The dedicated volume owner should retain this intent.

5. Clinical conditions and sterility

Any injection involves tissue trauma and potential inflammation or infection.

A contemporary urological review of penile-enhancement complications describes HA-related migration, nodules, Tyndall effect, phimosis and infection, and emphasises material-specific management.

Clinical safety therefore includes known material, an appropriate medical setting, sterile technique, relevant pre-procedure assessment and documentation.

Sterility does not eliminate every possible complication. It is one component of a broader system.

6. Follow-up is part of the procedure

Safety does not end when the injection ends.

Early swelling, tenderness or contour variation may occur, but clinicians may need to distinguish expected recovery from a developing complication.

Before treatment, a patient should understand:

what may be expected early
what symptoms should trigger contact
when follow-up is planned
who will assess a problem
where urgent care should be sought

This becomes particularly important for international patients.

If someone travels for penile filler and plans to fly home shortly afterwards, follow-up should be considered before treatment, not after a problem appears.

7. Complication preparedness matters

Being able to perform an injection is not the whole safety equation.

If a problem develops, the questions change:

Is this expected healing or a complication?
What material was used?
Is infection present?
Is there a vascular or tissue concern?
Is this migration, nodularity or contour irregularity?
Is observation enough?
Is targeted treatment required?
Is referral or emergency care needed?

This is why a vague promise that “we can just dissolve it” is medically incomplete.

Can hyaluronidase solve every complication?

No.

Hyaluronidase can break down hyaluronic acid and may be useful in selected confirmed HA-related situations.

That reversibility is clinically useful, but it is not a universal undo button.

Not every swelling, asymmetry, lump, infection, painful area or tissue problem should automatically be treated by dissolving filler.

The problem first needs to be identified.

Hyaluronidase also cannot be expected to dissolve a non-HA material.

Reversibility is a useful property, not a guarantee that every complication is easily reversible.

What complications have been reported?

Published literature describes:

swelling and bruising
tenderness
contour irregularity
asymmetry
palpable nodules
migration/displacement
inflammation
infection
foreskin-related problems in susceptible patients
rarer serious tissue or systemic events described in case literature

These problems do not have the same severity, cause or treatment.

Detailed assessment after a complication has developed belongs to the dedicated complication owner. This page is specifically for pre-procedure safety assessment.

Which symptoms need prompt medical assessment?

Prompt assessment may be appropriate for severe or rapidly worsening pain, marked or progressive colour change, rapidly increasing swelling, worsening redness or warmth, fever/systemic illness, purulent discharge, blistering or skin breakdown, significant difficulty passing urine or rapidly progressive tissue changes.

Chest pain, difficulty breathing, collapse or loss of consciousness are general medical emergencies and should not wait for routine online advice.

Ten questions to ask before penile filler

Who will actually perform the procedure?
What is the clinician’s official medical specialty?
What relevant experience do they have with penile anatomy, filler and complications?
What exactly will be injected?
Will product and batch information be documented?
How was the proposed volume selected?
Was the option of no procedure discussed?
What complications are possible?
What happens if I develop a problem?
What happens after I return home?

What may be warning signs when choosing where to have treatment?

No single feature automatically proves that a provider or facility is unsafe. However, further questions are reasonable when a fixed volume is recommended without meaningful assessment, every patient is offered the same amount, the material cannot be identified, batch documentation is unclear, the procedure is described as “no risk”, outcomes are guaranteed, complications are not discussed, no follow-up exists, it is unclear who would assess a problem, planning is based only on photographs or the clinician’s identity/qualification is unclear.

The purpose is not to rank doctors or clinics. It is to show patients what information matters.

What does “high-quality filler” actually mean?

“High-quality filler” is an imprecise marketing phrase.

More useful questions are: exact product, manufacturer, traceability, documented batch, appropriate storage, reason for selection and whether previous material is already present.

Product quality matters, but product quality alone cannot make an inappropriate treatment plan safe.

Why does provider selection matter?

There is no single sentence that defines one specialty as the only possible specialty for every penile cosmetic concern.

However, urological assessment may be particularly relevant where penile anatomy, erectile function, curvature, previous genital surgery, previous filler, urinary symptoms or complications are involved.

Formal specialty is only one factor. Relevant anatomy knowledge, procedure-specific experience, patient selection, complication recognition and follow-up planning also matter.

The provider-selection owner should keep that separate intent.

What should medical tourists consider?

Medical tourism adds a practical question:

Where will the patient be if a complication appears several days later?

Before travel, clarify how long to remain locally, when the first review is planned, who can be contacted after returning home, whether treatment records and product/batch details can be provided, where urgent care should be sought and what happens if reassessment is required.

A procedure may be short. The medical follow-up period is longer.

Is penile filler a “simple cosmetic procedure”?

The word “simple” can be misleading.

Penile filler is usually not the same as major genital surgery, but that does not mean it requires no medical assessment, has no meaningful risks or needs no follow-up.

Current EAU/ICSM guidance supports risk-benefit counselling, realistic expectations and individualized assessment.

Non-surgical does not mean medically trivial.

What is the main lesson from the Thailand case?

An elective injectable procedure needs a complete safety system.

patient selection → anatomy → material → planning → clinical conditions → follow-up → complication preparedness

For a patient:

Who? → What? → Why? → Follow-up? → What if something goes wrong?

Those questions are more informative than asking only “How many mL?” or “How much does it cost?”

Cem Özlük, MD: clinical perspective

Requested volume should not be the main decision point in penile filler assessment.

Baseline anatomy, previous procedures, existing filler, tissue characteristics, expectations, material properties and the ability to recognise/manage complications should be considered together.

Previous filler is particularly important. If another provider has already injected material, knowing what was injected, when, approximately how much and whether product documentation exists can be clinically useful.

When a problem already exists, the first question should not simply be “How can we improve the appearance?”

The priority is to determine what material is present and whether the finding represents expected healing, contour irregularity, migration, inflammation, infection or another complication.

Cem Özlük, MD has also discussed this complication-first framework in a professional article published by Medikal Akademi on 11 September 2026.

Frequently asked questions

Is penile filler completely safe?

No invasive procedure can be guaranteed to have zero risk. HA may have a comparatively favourable observed profile among studied materials, but complications can occur and long-term evidence remains limited.

Is hyaluronic acid safe for penile girth enhancement?

HA is among the materials studied for penile girth enhancement. Safety still depends on patient selection, anatomy, material, planning, clinical conditions and follow-up.

Does the ability to dissolve HA make treatment risk-free?

No. Hyaluronidase can be useful in selected HA-related situations, but infection, tissue injury and other complications cannot simply be described as instantly reversible.

Is a lump after penile filler always a complication?

Not necessarily. Early swelling or temporary irregularity may occur, but persistent, painful, inflamed or enlarging nodules should be medically assessed.

Which doctor should I see?

Formal specialty is one consideration. Relevant penile anatomy knowledge, experience, complication assessment and follow-up planning are also important.

Is travelling abroad for penile filler unsafe?

Risk is not determined by the country alone. Medical tourism adds follow-up, treatment-record, return-travel and emergency-access considerations.

Did 40 mL cause the Thailand death?

The inquest reporting included approximately 40 mL in the case history, but one case cannot establish a universal causal volume threshold.

Bottom line

Penile filler safety cannot be reduced to one brand, one number of millilitres, one technique or one appointment.

Current evidence suggests HA may have a more favourable observed complication profile than some permanent options, but more favourable does not mean risk-free.

A meaningful safety framework asks: